DK1123093T3 - Ubiquinonholdig sammensætning egnet til at fremme øget intramitochondrisk transport af ubiquinoner og fremgangsmåder til at anvende det - Google Patents

Ubiquinonholdig sammensætning egnet til at fremme øget intramitochondrisk transport af ubiquinoner og fremgangsmåder til at anvende det

Info

Publication number
DK1123093T3
DK1123093T3 DK99954343T DK99954343T DK1123093T3 DK 1123093 T3 DK1123093 T3 DK 1123093T3 DK 99954343 T DK99954343 T DK 99954343T DK 99954343 T DK99954343 T DK 99954343T DK 1123093 T3 DK1123093 T3 DK 1123093T3
Authority
DK
Denmark
Prior art keywords
intramitochondrial
ubiquinones
ubiquinone
transport
methods
Prior art date
Application number
DK99954343T
Other languages
Danish (da)
English (en)
Inventor
Janos Feher
Grazia Sears
Original Assignee
Sigma Tau Healthscience Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11343466&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1123093(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sigma Tau Healthscience Spa filed Critical Sigma Tau Healthscience Spa
Application granted granted Critical
Publication of DK1123093T3 publication Critical patent/DK1123093T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
DK99954343T 1998-10-21 1999-10-19 Ubiquinonholdig sammensætning egnet til at fremme øget intramitochondrisk transport af ubiquinoner og fremgangsmåder til at anvende det DK1123093T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1998BO000596A IT1304406B1 (it) 1998-10-21 1998-10-21 Preparazione per la veicolazione di principi attivi basata su acidigrassi polinsaturi del gruppo omega 3.
PCT/IT1999/000331 WO2000023069A1 (en) 1998-10-21 1999-10-19 Ubiguinone-containing composition suitable for promoting enhanced intramitochondrial transportation of ubiquinones and methods of using same

Publications (1)

Publication Number Publication Date
DK1123093T3 true DK1123093T3 (da) 2003-08-11

Family

ID=11343466

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99954343T DK1123093T3 (da) 1998-10-21 1999-10-19 Ubiquinonholdig sammensætning egnet til at fremme øget intramitochondrisk transport af ubiquinoner og fremgangsmåder til at anvende det

Country Status (11)

Country Link
US (1) US6417233B1 (de)
EP (1) EP1123093B1 (de)
AR (1) AR023338A1 (de)
AT (1) ATE237323T1 (de)
AU (1) AU1074600A (de)
DE (1) DE69907010T2 (de)
DK (1) DK1123093T3 (de)
ES (1) ES2196874T3 (de)
IT (1) IT1304406B1 (de)
PT (1) PT1123093E (de)
WO (1) WO2000023069A1 (de)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1307281B1 (it) 1999-11-25 2001-10-30 Simonelli Giuseppe Uso di ubichinone q10 per il trattamento locale e la prevenzione dipatalogie oftalmologiche secondarie alla terapia fotorefrattiva,
CN1638650A (zh) * 2001-03-09 2005-07-13 雀巢制品公司 改善与年龄有关的生理缺陷并延长寿命的组合物
ATE253353T1 (de) * 2001-04-12 2003-11-15 Vesifact Ag Coenzym q10 enthaltende mikroemulsion- prekonzentrate und mikroemulsionen
US6582723B2 (en) * 2001-05-03 2003-06-24 Wayne F. Gorsek Cancer immune composition for prevention and treatment of individuals
JP4603192B2 (ja) * 2001-05-10 2010-12-22 株式会社カネカ 毛髪頭皮用組成物
NZ529339A (en) * 2001-05-30 2004-08-27 Laxdale Ltd Coenzyme Q and eicosapentaenoic acid (EPA)
US7470659B2 (en) * 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
US20030229062A1 (en) * 2001-12-07 2003-12-11 The Regents Of The University Of California Treatments for age-related macular degeneration (AMD)
ITRM20010755A1 (it) * 2001-12-20 2003-06-20 Simonelli Giuseppe Uso del chinone q10 per il trattamento delle malattie oculari.
TW200302056A (en) * 2002-01-18 2003-08-01 Kaneka Corp Method for stabilizing reduced coenzyme Q10 and composition therefor
US6974592B2 (en) * 2002-04-11 2005-12-13 Ocean Nutrition Canada Limited Encapsulated agglomeration of microcapsules and method for the preparation thereof
JP4833553B2 (ja) * 2002-11-04 2011-12-07 オーシャン・ニュートリション・カナダ・リミテッド 複数の殻を有するマイクロカプセル及びそれらの調製方法
US20040208939A1 (en) * 2003-04-18 2004-10-21 Barry Sears Novel dietary compositions to reduce inflammation
US7875291B1 (en) 2003-09-05 2011-01-25 Glu-Pro, Inc. Composition for managing diabetes, obesity, and hyperlipidemia and associated methods
ITTO20030140U1 (it) * 2003-09-16 2005-03-17 Interfila Srl Matita cosmetica
TW200524579A (en) * 2003-11-28 2005-08-01 Kaneka Corp Composition for protecting liver functions
WO2005065672A1 (en) * 2004-01-08 2005-07-21 Kaneka Corporation Antiaging composition
ES2410587T3 (es) 2004-01-22 2013-07-02 University Of Miami Formulaciones tópicas de coenzima Q10 y métodos de uso
US7390507B2 (en) * 2004-04-13 2008-06-24 Ruwart Mary J Compositions and methods for the treatment of radiation burns and other traumatic skin conditions
DE102004041270A1 (de) * 2004-08-26 2006-03-02 Merz Pharma Gmbh & Co. Kgaa Ein Kapillar- Wirksystem enthaltende Zusammensetzungen mit anwendungsbezogener Differenzierbarkeit und deren Verwendung
US8034450B2 (en) * 2005-01-21 2011-10-11 Ocean Nutrition Canada Limited Microcapsules and emulsions containing low bloom gelatin and methods of making and using thereof
EP1846355B1 (de) * 2005-01-27 2009-12-16 Ocean Nutrition Canada Limited Fettsäure-benzenediol-derivate sowie herstellungs- und verwendungsverfahren dafür
US20080206316A1 (en) * 2005-01-27 2008-08-28 Colin Barrow Chromium-Fatty Acid Compounds and Methods of Making and Using Thereof
CA2610152C (en) * 2005-06-01 2018-04-10 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US9968120B2 (en) * 2006-05-17 2018-05-15 Dsm Nutritional Products Ag Homogenized formulations containing microcapsules and methods of making and using thereof
ES2823728T3 (es) * 2005-09-15 2021-05-10 Ptc Therapeutics Inc Variantes de cola de agentes terapéuticos con actividad redox para el tratamiento de enfermedades mitocondriales y otras afecciones y la modulación de biomarcadores de energía
CN101547687A (zh) * 2005-11-17 2009-09-30 生物药效率有限公司 生物相容的潜在乳化剂
EP2364701A1 (de) * 2005-12-20 2011-09-14 Cenestra, Llc Zubereitung enthaltend Omega 3 Fettsäuren
US20070184041A1 (en) * 2006-02-09 2007-08-09 Burja Adam M Methods and compositions related to production of coenzyme q10
EA019675B1 (ru) 2006-02-22 2014-05-30 Эдисон Фармасьютикалз, Инк. Редокс-активные терапевтические средства для лечения митохондриальных заболеваний и модуляции биомаркера коэнзима q
GB0604647D0 (en) * 2006-03-08 2006-04-19 Shchepinov Mikhail Stabilized food supplements and their derivatives
CA2643662A1 (en) * 2006-04-07 2007-10-25 Ocean Nutrition Canada Ltd. Emulsions and microcapsules with substances having low interfacial tension, methods of making and using thereof
US8491888B2 (en) * 2006-05-05 2013-07-23 Softgel Formulators, Inc. Highly absorbable coenzyme Q10 composition and method of producing same
CA2654031C (en) * 2006-06-05 2016-05-24 Ocean Nutrition Canada Limited Microcapsules with improved shells
KR100801057B1 (ko) * 2006-07-18 2008-02-04 삼성전자주식회사 컬러 보정 블럭을 구비하는 ｃｍｏｓ 이미지 센서 및 그이미지 센싱 방법
US8894993B2 (en) * 2006-08-04 2014-11-25 Natreon Inc. Mitochondria-targeted antioxidants
WO2008081989A1 (ja) * 2006-12-28 2008-07-10 Suntory Holdings Limited 神経再生剤
WO2008085997A2 (en) 2007-01-10 2008-07-17 Ocean Nutrition Canada, Ltd. Vegetarian microcapsules
HUP0700552A2 (en) * 2007-08-27 2009-03-30 Janos Dr Feher Method and composition inhibiting inflammation
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
KR100943652B1 (ko) * 2007-12-28 2010-02-25 (주)미토콘 생체이용율이 향상된 코엔자임큐10 함유 조성물
WO2009126764A1 (en) 2008-04-11 2009-10-15 Cytotech Labs, Llc Methods and use of inducing apoptosis in cancer cells
US8535660B1 (en) 2008-05-27 2013-09-17 Argent Development Group, Llc Nutritional supplements for pregnant women
US8535659B1 (en) 2008-05-27 2013-09-17 Argent Development Group, Llc Nutritional supplements for pregnant women
BRPI0918139B1 (pt) 2008-09-10 2024-04-30 Ptc Therapeutics, Inc Composição, alimento medicinal ou funcional, suplemento alimentar ou dietético para tratamento de distúrbios de desenvolvimento pervasivos com terapêuticos redox-ativos
US8993625B2 (en) 2009-03-11 2015-03-31 Stable Solutions Llc Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle
US9034389B2 (en) 2009-03-11 2015-05-19 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
US20110071090A1 (en) * 2009-03-11 2011-03-24 Stable Solutions Llc Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
IT1393419B1 (it) 2009-03-19 2012-04-20 Medivis S R L Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6.
US9005608B2 (en) * 2009-03-24 2015-04-14 Adds Pharmaceuticals Llc Stabilized solubility-enhanced formulations for oral delivery
EA023913B1 (ru) 2009-05-11 2016-07-29 БЕРГ ФАРМА ЭлЭлСи Способы лечения метаболических нарушений, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
AU2010313249B2 (en) 2009-10-30 2016-05-19 Biojiva Llc Alleviating oxidative stress disorders with PUFA derivatives
KR101907411B1 (ko) * 2010-03-12 2018-10-12 베르그 엘엘씨 코엔자임 Ｑ10(ＣｏＱ10)의 정맥내 제형 및 이의 사용 방법
CN103608323B (zh) 2011-04-04 2016-08-17 博格有限责任公司 治疗中枢神经系统肿瘤的方法
JP6145087B2 (ja) 2011-04-26 2017-06-07 レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． Ｐｕｆａ酸化関与障害
KR102020611B1 (ko) 2011-04-26 2019-09-10 레트로토프 인코포레이티드 Ｐｕｆａ와 관련된 신경퇴행성 질환 및 근육 질환
KR102110200B1 (ko) 2011-04-26 2020-05-13 레트로토프 인코포레이티드 산화성 망막 질환
KR102020579B1 (ko) 2011-04-26 2019-09-10 레트로토프 인코포레이티드 에너지 프로세싱 손상 장애 및 미토콘드리아 결함
WO2012174286A1 (en) * 2011-06-14 2012-12-20 Edison Pharmaceuticals, Inc. Catechol derivatives for treatment of oxidative stress diseases
CN107095863A (zh) 2011-06-17 2017-08-29 博格有限责任公司 可吸入药物组合物
US20140274966A1 (en) * 2013-03-14 2014-09-18 Hygia Pharmaceuticals, Llc Drink Product Containing Genistein and Use Thereof
EP2983654B1 (de) 2013-04-08 2025-11-12 BPGbio, Inc. Behandlung von krebs mit coenzym-q10-kombinationstherapien
CA2916513A1 (en) * 2013-07-03 2015-01-08 Barrie Tan Coq10 (ubiquinone, ubiquinol), vitamin a (retinoic acid, retinol), vitamin e (tocotrienol, tocopherol) and methods of use
WO2015035094A1 (en) 2013-09-04 2015-03-12 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme q10
US9138453B2 (en) 2013-10-14 2015-09-22 Biomarker Pharmaceuticals, Inc. Nutrient combinations for affecting an aging process
US20170189350A1 (en) 2015-11-16 2017-07-06 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
CN108698987B (zh) 2015-11-23 2021-07-13 乐巢拓普有限公司 1,4-二烯体系的位点特异性同位素标记
DE202015106479U1 (de) 2015-11-29 2016-03-09 Cathleen Straßburger Stapelhilfe und Abdeckhaube für den Transport von Cateringmaterial zum Kunden
CN113024369A (zh) 2015-12-17 2021-06-25 Ptc医疗公司 用于治疗氧化应急障碍的化合物
KR20260018193A (ko) 2020-02-21 2026-02-06 레트로토프 인코포레이티드 고도불포화 지방산 및 이의 유도체의 동위원소 변형을 위한 공정
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5618914A (en) * 1979-07-25 1981-02-23 Eisai Co Ltd Ubidecarenone composition having good absorbability
DE3224619A1 (de) 1981-07-14 1983-05-19 Freund Industrial Co., Ltd., Tokyo Orale pharmazeutische zusammensetzung
JP2643217B2 (ja) 1988-01-22 1997-08-20 エーザイ株式会社 脂溶性物質水性液
US5895652A (en) 1996-07-29 1999-04-20 Longevity Institute International Method of metabolic adjuvanation and cellular repair
NO304009B1 (no) 1997-02-04 1998-10-12 Gunnar Volden Hudpreparat
CA2260397A1 (en) * 1999-01-29 2000-07-29 Atlantis Marine Inc. Method of converting rendered triglyceride oil from marine sources into bland, stable food oil

Also Published As

Publication number Publication date
ITBO980596A1 (it) 2000-04-21
PT1123093E (pt) 2003-09-30
IT1304406B1 (it) 2001-03-19
AU1074600A (en) 2000-05-08
EP1123093A1 (de) 2001-08-16
ITBO980596A0 (it) 1998-10-21
US6417233B1 (en) 2002-07-09
WO2000023069A1 (en) 2000-04-27
ATE237323T1 (de) 2003-05-15
EP1123093B1 (de) 2003-04-16
ES2196874T3 (es) 2003-12-16
DE69907010T2 (de) 2004-02-19
AR023338A1 (es) 2002-09-04
DE69907010D1 (de) 2003-05-22

Similar Documents

Publication Publication Date Title
DK1220849T3 (da) Sammensætninger med bicykliske forbindelser og fremgangsmåde til stabilisering heraf
DE69928270D1 (de) Neutraler aminosäurentransporter und korrespondierendes gen
DE69918233D1 (de) Polymilchsäure zusammensetzung und daraus hergestellter film
NO991151D0 (no) Forbindelse og anvendelse derav
IS5943A (is) Aðferð og samsetningar til að endurheimta samræmdan stöðugleika próteina af p53 ættinni
NO20031152D0 (no) Befruktningshindrende fremgangsmåte og administrasjonsform for det samme
DK0980240T3 (da) Sammensætninger med lang frigivelse og fremgangsmåde til fremstilling heraf
DK0975708T3 (da) Fremgangsmåder og materialer til nedbrydning af xanthan
NO993217L (no) Broenntetningssammensetninger og fremgangsmåter
DK1454907T3 (da) Quninazolin og pyridopyrmidin-derivativer
DK1121192T3 (da) Fremgangsmåde til homogenisering
DK1112174T3 (da) Isosorbidholdige polyestere og fremgangsmåder til fremstiling heraf
NO20006488D0 (no) Sammensetning og anvendelse
FI990965A7 (fi) Menetelmä kanavaestimaatin muodostamiseksi ja vastaanotin
DK199900234U4 (da) Paroxetin-methansulfonat i krystallinsk form, farmaceutisk præparat indeholdende dette og andvendelse af forbindelsen til f
DK1372686T3 (da) Fremgangsmåder og sammensætninger til peptidsyntese
AU1074600A (en) Ubiguinone-containing composition suitable for promoting enhanced intramitochondrial transportation of ubiquinones and methods of using same
ATE220304T1 (de) Servier- und transportaufnahme
NO20023815D0 (no) Publikumsmålingssystem og fremgangsmåte for digital kringkasting
DK0991415T3 (da) Faste, oralt indgivelige dosisformer for ribavirin og fremgangsmåde til fremstilling af disse
DK1092079T3 (da) Metode til fremstilling af en gassammensætning og anvendelse deraf
DK1003383T4 (da) Smagsforstærkende N-ethyl-p-menthan-3-carboxamidindeholdende forbindelser og fremgangsmåde til fremstilling og anvendelse deraf
DK1131083T3 (da) Anvendelse af væksthormonfrigørende forbindelser og antagonister deraf til behandling af tumorer
NO995073L (no) Fjærnaktivert og låst muffeklemme
DK0905128T3 (da) Fremgangsmåder og mellemprodukter egnede til fremstilling af antifolater